肺免疫预后指数(LIPI)作为转移性肾细胞癌预后生物标志物的验证
研究利用三项前瞻性研究的患者数据,评估治疗前肺免疫预后指数(LIPI)在转移性肾细胞癌中的预后价值。LIPI基于中性粒细胞与(白细胞减中性粒细胞)比值>3及乳酸脱氢酶>正常上限计算。结果显示LIPI与接受免疫检查点抑制剂或抗血管生成治疗的转移性肾细胞癌患者的总生存期和无进展生存期相关,证实其预后作用。
要点
- LIPI良好组与中间/差组相比,纳武利尤单抗数据集总生存期30.1个月 vs 13.8个月,HR=0.47。
- CheckMate214中纳武利尤单抗-伊匹木单抗组LIPI良好 vs 中间/差组总生存期HR=0.55(p<0.0001)。
- CheckMate214中舒尼替尼组LIPI良好 vs 中间/差组总生存期HR=0.38(p<0.0001)。
核心结论
- 治疗前LIPI与接受免疫检查点抑制剂或抗血管生成治疗的转移性肾细胞癌患者较差的生存结局相关,证实LIPI在转移性肾细胞癌中的预后作用与所用全身治疗无关。
研究设计与样本
- 研究使用三项前瞻性研究的患者水平数据:NIVOREN试验(纳武利尤单抗)、TORAVA试验(VEGF/VEGFR靶向治疗)和CheckMate 214(纳武利尤单抗-伊匹木单抗 vs 舒尼替尼)。
- LIPI基于衍生中性粒细胞/(白细胞-中性粒细胞)比值>3和乳酸脱氢酶>正常上限计算,分为三组(LIPI良好0个因素、LIPI中间1个因素、LIPI差2个因素)和/或两组(LIPI良好0个因素、LIPI中间/差1-2个因素),分组依据试验样本量。
- 主要终点为总生存期,次要终点为无进展生存期。
主要发现
- 在纳武利尤单抗数据集(n=619)中,LIPI与总生存期显著相关(LIPI良好30.1个月 vs LIPI中间/差13.8个月;HR=0.47),与无进展生存期也相关(HR=0.74)。
- 在VEGF/VEGFR靶向治疗数据集(n=159)中,仅观察到与无进展生存期的相关性。
- 在CheckMate214数据集(n=1084)中,单变量和多变量分析显示LIPI在两个治疗组中均与总生存期显著相关:纳武利尤单抗-伊匹木单抗组LIPI良好 vs 中间/差HR=0.55(p<0.0001);舒尼替尼组LIPI良好 vs 中间/差HR=0.38(p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients. METHODS: We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib). LIPI was calculated based on a derived neutrophils/(leukocyte-neutrophil) ratio > 3 and lactate-dehydrogenase >upper limit of normal, classifying patients into three groups (LIPI good, 0 factors;LIPI intermediate (int), 1 factor;LIPI poor, 2 factors) and/or into two groups (LIPI good, 0 factors;LIPI int/poor, 1-2 factors) according to trial sample size. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS). RESULTS: In the Nivolumab dataset (n = 619), LIPI was significantly associated with OS (LIPI-good 30.1 vs 13.8 months in the LIPI int/poor; HR= 0.47) and PFS (HR=0.74). In the VEGF/VEGFR-TT dataset (n = 159), only a correlation with PFS was observed. In the CheckMate214 dataset (n = 1084), LIPI was significantly associated with OS (nivolumab-ipilimumab OS LIPI good vs int/poor: HR=0.55, p < 0.0001; sunitinib: OS LIPI good vs int/poor: 0.38, p < 0.0001) in both treatment groups in univariate and multivariate analysis. CONCLUSIONS: Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.
引用
- Carril-Ajuria L, Lavaud P, Dalban C, et al. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. Eur J Cancer. 2024. PMID: 38653033. doi:10.1016/j.ejca.2024.114048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。